Here is Eli Lilly's competitive edge in GLP-1 obesity drugs and Abbott's secondary play

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.)

Source link

About The Author

Scroll to Top